Immunology and Bi...
Follow
Find
6.0K views | +3 today
 
Scooped by Gilbert Faure au nom de l'ASSIM
onto Immunology and Biotherapies
Scoop.it!

Miraculous transplantation of a leg » Retronaut

Miraculous transplantation of a leg » Retronaut | Immunology and Biotherapies | Scoop.it
Miraculous transplantation of a leg - A verger's dream: Saints Cosmas and Damian performing a miraculous cure by transplantation of a leg.
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

HLA antibody screening in kidney transplantation: current guidelines - Springer

HLA antibody screening in kidney transplantation: current guidelines - Springer | Immunology and Biotherapies | Scoop.it
HLA antibody screening in kidney transplantation: current guidelines http://t.co/xp710WQgyj
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Ex Vivo-Expanded but Not In Vitro-Induced Human Regulatory T Cells Are Candidates for Cell Therapy in Autoimmune Diseases Thanks to Stable Demethylation of the FOXP3 Regulatory T Cell-Specific Deme...

Regulatory T cell (Treg) therapy is a promising approach for transplant rejection and severe autoimmunity. Unfortunately, clinically meaningful Treg numbers can be obtained only upon in vitro culture.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer

Selective Bispecific T Cell Recruiting Antibody and Antitumor Activity of Adoptive T Cell Transfer | Immunology and Biotherapies | Scoop.it
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer http://t.co/yi4WBhIAcA
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

European Medicines Agency - News and Events - First stem-cell therapy recommended for approval in EU

European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 20, 11:46 AM
First stem-cell therapy recommended for approval in EU

New treatment for rare condition caused by burns to the eye


The applicant for Holoclar is Chiesi Farmaceutici S.p.A.The active substance of Holoclar is ex-vivo expanded autologous human corneal epithelial cells containing stem cells.Holoclar was designated as an orphan medicine and an advanced therapy medicinal product (ATMP) and EMA provided protocol assistance to the applicant during the development of the medicine on multiple occasions. Both orphan and ATMP designations and the associated incentives, such as free scientific advice or protocol assistance, are among the Agency’s most important instruments to encourage the development of medicines for patients suffering from rare diseases, and the development of innovative medicinal products.


Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Preclinical screening for acute toxicity of therapeutic monoclonal antibodies ... - Nature.com

Preclinical screening for acute toxicity of therapeutic monoclonal antibodies ... - Nature.com | Immunology and Biotherapies | Scoop.it
Clinical & Translational Immunology focuses on the general functioning of the immune system in its broadest sense, with a particular emphasis on its cell biology.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia — NEJM

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia — NEJM | Immunology and Biotherapies | Scoop.it
Original Article from The New England Journal of Medicine — Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Regulation of advanced therapy medicinal products will affect the practice of ... - Nature.com

Regulation of advanced therapy medicinal products will affect the practice of ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Ossianix › Science and Technology

Ossianix › Science and Technology | Immunology and Biotherapies | Scoop.it

Sharks are the most evolutionarily ancient animal species to possess an adaptive immune system similar to humans, including the production of antibodies against invading pathogens. These ancestral antibodies called IgNARs for Immunoglobulin New Antigen Receptors have a number of remarkable and unique properties. IgNARs evolved as heavy chain only antibodies without the associated light chains found in human antibodies. Their individual variable domains (known as VNARs) are highly soluble compared to the human variable domains, which on their own are generally insoluble and aggregate. Additionally, VNARs are particularly stable and bind antigens under conditions that match, which would disrupt the integrity of most mammalian antibodies. Furthermore, shark antibodies are believed to be particularly stable since they evolved under the high osmolarity of shark blood, which is maintained by the protein denaturant urea.


Only a very small region at the tip of an antibody directly binds to an antigen and sharks have evolved a unique way of engaging target antigens. The diversity of human antibodies is generated by a complex of two variable domains (VH and VL) each of which has three sites of contact called complementarity-determining regions (CDR 1-3). Thus, antibodies rely on contributions from up to 6 CDRs, which create a relatively flat surface of for antigen binding. By contrast, VNAR single domains of shark antibodies lack a CDR2 and concentrate diversity in an extended CDR3 loop supported by a smaller CDR1 that preferentially seeks out cavities and buried epitopes. Additionally, the position of disulfide bridges that affect the stability, flexibility and orientation of the CDR3 loop create diverse isoforms (called type I, II and IV) that can recognize a wide array of antigens.

 

VNARs are the smallest known immunoglobulin-based antigen binding domains that can have agonistic or antagonistic effects on their own. Their unique combination of structural and biophysical properties makes them attractive building blocks for drug discovery applications, particularly in situations where monoclonal antibodies have proven to be less than ideal. Such examples include perturbation of protein-protein interactions and for targeting difficult but important target classes such as transporters, ion channels and G protein-coupled receptors and cell-surface carbohydrates. A new generation of modular therapeutic agents can be custom built with innovative functions beyond the reach of classical antibodies for the treatment of a broad range of human diseases.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 17, 6:32 AM
Flexible Formatting Platform: The VNAR platform is very versatile and a wide array of novel therapeutic products with different valency and specificity options can be readily produced. Mono- or bivalent antigen binding molecules can be developed with different half-lives, depending on the therapeutic indication. Half-life extension of products can be readily achieved by using either a VNAR reactive with human serum albumin or the Fc domain from human IgG. Effector functions can also be engineered for reduced or enhanced cytotoxicity as required.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Plantibodies Could Pave the Road to Wellness - Newsweek

Plantibodies Could Pave the Road to Wellness - Newsweek | Immunology and Biotherapies | Scoop.it
Newsweek Plantibodies Could Pave the Road to Wellness Newsweek The “plantibody,” as this and other antibodies grown in plants have been dubbed by the handful of companies that develop them, is the product of decades of sky-high hopes and...

Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

the dream of decades may decrease the costs of MoAbs?

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells- Nature.com

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory  T cells- Nature.com | Immunology and Biotherapies | Scoop.it
Abstract

CD4+CD25+ regulatory T cells (Tregs) represent a specialized subpopulation of T cells, which are essential for maintaining peripheral tolerance and preventing autoimmunity. The immunomodulatory effects of Tregs depend on their activation status. Here we show that, in contrast to conventional anti-CD4 monoclonal antibodies (mAbs), the humanized CD4-specific monoclonal antibody tregalizumab (BT-061) is able to selectively activate the suppressive properties of Tregs in vitro. BT-061 activates Tregs by binding to CD4 and activation of signaling downstream pathways. The specific functionality of BT-061 may be explained by the recognition of a unique, conformational epitope on domain 2 of the CD4 molecule that is not recognized by other anti-CD4 mAbs. We found that, due to this special epitope binding, BT-061 induces a unique phosphorylation of T-cell receptor complex-associated signaling molecules. This is sufficient to activate the function of Tregs without activating effector T cells. Furthermore, BT-061 does not induce the release of pro-inflammatory cytokines. These results demonstrate that BT-061 stimulation via the CD4 receptor is able to induce T-cell receptor-independent activation of Tregs. Selective activation of Tregs via CD4 is a promising approach for the treatment of autoimmune diseases where insufficient Treg activity has been described. Clinical investigation of this new approach is currently ongoing.


Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:

a functionnal cellular specificity? a major breakthrough?

more...
Krishan Maggon 's curator insight, December 17, 7:19 AM

Immunology and Cell Biology advance online publication 16 December 2014; doi: 10.1038/icb.2014.102

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway
OPEN

Bianca Helling1, Martin König1, Benjamin Dälken1, Andre Engling1, Wolfgang Krömer1, Katharina Heim1, Holger Wallmeier2, Jürgen Haas3, Brigitte Wildemann3, Brigitte Fritz3, Helmut Jonuleit4, Jan Kubach4, Theodor Dingermann5, Heinfried H Radeke6, Frank Osterroth1, Christoph Uherek1, Niklas Czeloth1,7 and Jörg Schüttrumpf1,7

Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Abzena/Polytherics - Antibody Drug Conjugates

Abzena/Polytherics - Antibody Drug Conjugates | Immunology and Biotherapies | Scoop.it

PolyTherics has developed its range of novel ThioBridge™ linkers to efficiently conjugate drugs to antibodies to create less heterogeneous ADCs with better stability. Our proprietary technology uses site-specific conjugation to naturally occurring inter-chain disulfides avoiding the need for antibody re-engineering to create a site of attachment.

We offer a range of cytotoxic payloads with different mechanisms of action which we can conjugate to your antibody using our ThioBridge™ technology. These payloads have been developed internally or are accessed through our partnerships.

PolyTherics can undertake the conjugation and analytical characterisation of the ADC in its own laboratories or provide a ThioBridge™ precursor reagent to you to use in-house. In addition to producing ADCs for potential therapeutic use, we can also produce antibody-conjugates for diagnostic & imaging purposes and ADCs using standard conjugation technologies for comparative purposes.

 

Optimisation of pharmacokineticsPolyTherics provides a range of site-specific conjugation technologies to optimise the pharmacokinetics (PK) and pharmacodynamics (PD) of therapeutic peptides and proteins, including antibody fragments and other protein scaffolds, by extending their half-life to reduce the frequency of dosing. This improves patient compliance and can reduce the cost of treatment. PolyTherics also provides a low viscosity polymer, PolyPEG™, to enable the easier injection of conjugated proteins which need to be administered at high concentration. 

Our proprietary PEGylation technologies enable polyethylene glycol (PEG) or other polymers to be attached to different specified sites depending on the nature of the protein. TheraPEG™ conjugates PEG at disulfide bonds, HiPEG™ conjugates PEG to poly-histidine motifs and CyPEG™ conjugates PEG to a thiol on a free cysteine. These technologies are used to conjugate both linear and branched PEG to therapeutic proteins and can be used for PolyPEG™ conjugation.

The conjugation processes are efficient, helping keep the cost of manufacture down, and the conjugated products are more stable and homogeneous than can be achieved with other well-established conjugation technologies.

We can PEGylate your protein or peptide in our laboratories or provide you with our conjugation reagents so you can undertake the work yourself. Our reagents are available in a range of PEG molecular weights and formats, including linear and branched PEGs.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 16, 6:25 AM

Humanized antibodies and deimmunised proteins are designed to be devoid of the T cell epitopes that lead to an adverse immune response while minimising the loss of antibody affinity or protein activity that can occur with standard protein engineering techniques.

 

 Composite Human Antibodies™
Antibody humanization technology is used to generate humanized and fully functional antibodies devoid of T cell epitopes in the variable region sequences to reduce immunogenicity in patients.  Composite Proteins™
Protein deimmunisation technology is used to generate therapeutic proteins devoid of human T cell epitopes to minimise potential immunogenicity in patients without compromising protein activity
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Biotherapeutics need general chapters not individual Ph. Eur. monographs says ... - BioPharma-Reporter.com

Biotherapeutics need general chapters not individual Ph. Eur. monographs says ... - BioPharma-Reporter.com | Immunology and Biotherapies | Scoop.it
Generic drugmakers want biotherapeutic products to have general recommendations in the European Pharmacopoeia rather than individual monographs.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Clinical blockade of PD1 and LAG3 [mdash] potential mechanisms of action : Nature Reviews Immunology : Nature Publishing Group

Clinical blockade of PD1 and LAG3 [mdash] potential mechanisms of action : Nature Reviews Immunology : Nature Publishing Group | Immunology and Biotherapies | Scoop.it

Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, December 24, 3:06 AM
Clinical blockade of PD1 and LAG3 — potential mechanisms of actionLinh T. Nguyen& Pamela S. OhashiAffiliationsCorresponding authorsNature Reviews Immunology 15, 45–56 (2015) doi:10.1038/nri3790Published online 23 December 2014
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Generation of a highly specific monoclonal anti-infliximab a... : Therapeutic Drug Monitoring

Background: Determination of infliximab (IFX) serum concentrations has been used for treatment optimization of patients with inflammatory bowel disease (IBD). A wide range of ELISA assays exists to quantitate IFX.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

New Dengue-Detecting Antibodies - Scientist (blog)

New Dengue-Detecting Antibodies - Scientist (blog) | Immunology and Biotherapies | Scoop.it
Researchers uncover a class of antibodies that may confer immunity to different serotypes of the dengue virus.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Candidin and trichophytin stimulate the production of Th1 and regulatory cytokines by peripheral blood mononuclear cells: implication for their use as adjuvants in immunotherapy, Immunotherapy, Fut...

Candidin and trichophytin stimulate the production of Th1 and regulatory cytokines by peripheral blood mononuclear cells: implication for their use as adjuvants in immunotherapy, Immunotherapy, Fut... | Immunology and Biotherapies | Scoop.it
Candidin and trichophytin stimulate the production of Th1 and regulatory cytokines by peripheral blood mononuclear... http://t.co/DUXvBIV7Mz
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Another Alzheimer's Antibody Goes Down. In the Pipeline:

Another Alzheimer's Antibody Goes Down. In the Pipeline: | Immunology and Biotherapies | Scoop.it
Another Alzheimer's Antibody Goes Down: The clinical failure rate for disease-modifying Alzheimer's therapies ... http://t.co/p6ikkjCHYF
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Cancer's Next Big Thing -- Immunotherapy - Huffington Post

Cancer's Next Big Thing -- Immunotherapy - Huffington Post | Immunology and Biotherapies | Scoop.it
While it's true that even immunotherapies are not side-effect free, they pale in comparison to traditional chemotherapy and, by fortifying immune systems, bring the promise of creating healthier bodies that beat back the disease, and mitigate side...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

New class of synthetic molecules mimics antibodies

New class of synthetic molecules mimics antibodies | Immunology and Biotherapies | Scoop.it
RT @_bioengineer: #Immunology #SyntheticBiology New class of synthetic molecules ... - Read more: http://t.co/WiXJO7rTHc http://t.co/pEVbOn…
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Humoral and cell-mediated immune responses elicited by poly (DL-lac... - PubMed - NCBI

Drug Deliv. 2014 May;21(3):233-41. doi: 10.3109/10717544.2013.848494. Epub 2013 Oct 30.
Gilbert Faure au nom de l'ASSIM's insight:

a filarial adjuvant

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498, Expert Opinion on Therapeutic Patents, Informa Healthcare

Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498, Expert Opinion on Therapeutic Patents, Informa Healthcare | Immunology and Biotherapies | Scoop.it
L is for CLL treatments #AntibodyAtoZ Check out our review of anti-CD44 antibody for B-cell leukemia http://t.co/922YdzsVQe @DrugPatentWatch
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Antibody Therapies Entering 2015 - Total Biopharma : Total Biopharma

Antibody Therapies Entering 2015 - Total Biopharma : Total Biopharma | Immunology and Biotherapies | Scoop.it
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Virology and Bioinformatics from Virology.ca
Scoop.it!

Virology Journal | Full text | Plant-based vaccines against viruses

Plant-made or “biofarmed” viral vaccines are some of the earliest products of the technology of plant molecular farming, and remain some of the brightest prospects for the success of this field. Proofs of principle and of efficacy exist for many candidate viral veterinary vaccines; the use of plant-made viral antigens and of monoclonal antibodies for therapy of animal and even human viral disease is also well established. This review explores some of the more prominent recent advances in the biofarming of viral vaccines and therapies, including the recent use of ZMapp for Ebolavirus infection, and explores some possible future applications of the technology.

Via Chris Upton + helpers
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

B7-H3 And PD-1: Are All Checkpoint Inhibitors Created Equal? (MGNX) - Seeking Alpha

B7-H3 And PD-1: Are All Checkpoint Inhibitors Created Equal? (MGNX) - Seeking Alpha | Immunology and Biotherapies | Scoop.it

Checkpoint inhibitors are a big deal. What started with ipilimumab has now grown into a class of drugs which are being pursued vigorously by nearly every major pharmaceutical company in the world. In this crowded space, it's worth noting that B7-H3 is only being pursued by one company, MacroGenics (NASDAQ:MGNX).


Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Journal of Investigative Dermatology - Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

Journal of Investigative Dermatology - Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes | Immunology and Biotherapies | Scoop.it
The Journal of Investigative Dermatology publishes basic and clinical research in cutaneous biology and skin disease.
more...
Krishan Maggon 's curator insight, December 16, 2:07 AM

Journal of Investigative Dermatology (2015) 135, 31–38; doi:10.1038/jid.2014.295; published online 14 August 2014

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

Denis Jullien1, Jörg C Prinz2 and Frank O Nestle3